biote Corp.
BTMDDrugs in Pipeline
8
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
26dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How BTMD's past catalysts played out
Sunitinib
Metastatic Renal Cell Carcinoma
Basic treatment
Systemic Sclerosis
IMA402 (Phase Ia)
Refractory Cancer
Endoxana, Leukine, IMA910
Colorectal Carcinoma
KL003 Cell Injection Drug Product
Transfusion-dependent Beta-Thalassemia
donor-derived NK cell infusion
Non-small Cell Lung Cancer
RY_SW01 cell injection
Lupus Nephritis
Endoxana, IMA901, Leukine
Renal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sunitinib | Phase 3 | Metastatic Renal Cell Carcinoma | - | - |
Basic treatment | Phase 2 | Systemic Sclerosis | - | - |
IMA402 (Phase Ia) | Phase 2 | Refractory Cancer | - | - |
Endoxana, Leukine, IMA910 | Phase 2 | Colorectal Carcinoma | - | - |
KL003 Cell Injection Drug Product | Phase 2 | Transfusion-dependent Beta-Thalassemia | - | - |
donor-derived NK cell infusion | Phase 2 | Non-small Cell Lung Cancer | - | - |
RY_SW01 cell injection | Phase 2 | Lupus Nephritis | - | - |
Endoxana, IMA901, Leukine | Phase 2 | Renal Cell Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in biote Corp.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in biote Corp.'s (BTMD) pipeline across Phase 3, Phase 2. Its lead program is Sunitinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is biote Corp.'s next FDA catalyst?→
biote Corp.'s (BTMD) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BTMD biotech catalysts?→
Add BTMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow biote Corp.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.